BUSINESS SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table is a summary of segment information for the years ended December 31, 2019, 2018 and 2017. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.

	2019			2018			2017
Net revenues:
DIS business	$	7,405		$	7,204		$	7,068
All other operating segments	321			327			334
Total net revenues	$	7,726		$	7,531		$	7,402
Operating earnings (loss):
DIS business	$	1,298		$	1,235		$	1,313
All other operating segments	42			47			52
General corporate activities	(109		)	(181		)	(200		)
Total operating income	1,231			1,101			1,165
Non-operating expenses, net	(155		)	(175		)	(135		)
Income from continuing operations before income taxes and equity in earnings of equity method investees	1,076			926			1,030
Income tax expense	(247		)	(182		)	(241		)
Equity in earnings of equity method investees, net of taxes	57			44			35
Income from continuing operations	886			788			824
Income from discontinued operations, net of taxes	20			—			—
Net income	906			788			824
Less: Net income attributable to noncontrolling interests	48			52			52
Net income attributable to Quest Diagnostics	$	858		$	736		$	772

Depreciation and amortization expense for the years ended December 31, 2019, 2018 and 2017 were as follows:

	2019		2018		2017
DIS business	$	226	$	213	$	189
All other operating segments	6		6		6
General corporate	97		90		75
Total depreciation and amortization	$	329	$	309	$	270

Capital expenditures for the years ended December 31, 2019, 2018 and 2017 were as follows:

	2019		2018		2017
DIS business	$	373	$	330	$	219
All other operating segments	20		16		15
General corporate	7		37		18
Total capital expenditures	$	400	$	383	$	252

Net revenues by major service for the years ended December 31, 2019, 2018 and 2017 were as follows:

	2019		2018		2017
Routine clinical testing services	$	4,206	$	4,217	$	4,006
Gene-based and esoteric (including advanced diagnostics) testing services	2,620		2,409		2,449
Anatomic pathology testing services	579		578		612
All other	321		327		335
Total net revenues	$	7,726	$	7,531	$	7,402